Journal of Cancer Science and Research
Open Access

Rodrigo Erlich

Publications

• Case Report
  Clinical Utility of Target Selector™ ctDNA Testing: Detection of EGFR Mutations via Liquid Biopsy Enabled Targeted Therapy Selection for Patients with Advanced NSCLC
  Author(s): Veena M Singh, Rodrigo Erlich and Cecile Rose T VibatVeena M Singh, Rodrigo Erlich and Cecile Rose T Vibat
  
  Background: Molecular profiling of tumors provides information key for devising personalized therapeutic strategies for managing disease in cancer patients. A liquid biopsy is emerging as a sensitive means to evaluate biomarker status without the complications and costs associated with surgical biopsies, particularly for patients unable or unwilling to undergo invasive procedures. Materials and Methods: Patient blood specimens were collected in Biocept’s proprietary Blood Collection Tubes for liquid biopsy testing in Biocept’s CLIA-certified, CAP-accredited laboratory. Dual Circulating Tumor Cell (CTC) and circulating tumor DNA (ctDNA) platforms were utilized to detect ALK or ROS1 gene rearrangements by FISH, or EGFR mutations, respectively. Results: Described are three metastatic NSCLC patients for which liq.. View More»
  DOI: 10.4172/2576-1447.1000113

  Abstract PDF

Relevant Topics